<DOC>
	<DOCNO>NCT02467868</DOCNO>
	<brief_summary>This Multicenter , Double-Blind , Randomized , Comparative Efficacy Safety Study MYL-1401H Neulasta ( Pegfilgrastim ) Stage II/III Breast Cancer Patients Receiving Neoadjuvant Adjuvant Chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Study With MYL-1401H Neulasta</brief_title>
	<detailed_description>After successful screening , eligible patient randomly allocate one two study arm , either receive MYL-1401H Neulasta . Randomization 2:1 MYL-1401H Neulasta , respectively . Subjects receive first six cycle background therapy ( Docetaxel , Doxorubicin , Cyclophosphamide [ TAC ] ) day 1 . Treatment study drug ( either MYL-1401H Neulasta ) schedule Day 2 cycle , least 24 hour chemotherapy administration . Duration cycle 3 week . Follow-up visit schedule 24 week first administration study drug .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Signed date write informed consent . Patients ≥18 year . Women childbearing potential must agree use effective method birth control treatment period first dose study drug 6 month follow last dose study drug . Newly diagnose , pathologically confirm breast cancer . Stage II III breast cancer adequate stag workup adequate surgery receive adjuvant therapy . Patients planned/eligible receive neoadjuvant adjuvant treatment ( Docetaxel , Doxorubicin , Cyclophosphamide [ TAC ] ) breast cancer . Cancer Chemotherapy Radiotherapy naïve . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Absolute neutrophil count ≥ 1.5 × 109/L ; Platelet count ≥ 100 × 109/L ; Hemoglobin &gt; 10 g/dL without blood transfusion cytokine support two week previous hemoglobin level . Adequate cardiac function ( include leave ventricular ejection fraction ≥ 50 % assessed echocardiography ) within 4 week prior start chemotherapy . Adequate renal function , i.e. , creatinine &lt; 1.5 × upper limit normal ( ULN ) . Other protocol specific inclusion/exclusion criterion may apply Participation clinical trial receive investigational drug within 28 day randomization . Previous exposure filgrastim , pegfilgrastim , lenograstim , lipegfilgrastim , filgrastim form market clinical development . Received blood transfusion erythroid growth factor within 2 week prior first dose chemotherapy . Known hypersensitivity drug excipients patient receive study . Known hypersensitivity E. coliderived product . Known fructose intolerance ( related sorbitol excipient ) . Underlying neuropathy grade 2 high . Active infectious disease medical condition might put patient significant risk tolerate 6 course TAC chemotherapy ( e.g. , recent myocardial infarction ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 × Upper limit normal ( ULN ) , ALT and/or AST &gt; 1.5 × ULN alkaline phosphatase ( ALP ) &gt; 2.5 × ULN ; bilirubin &gt; ULN . Treatment systemically active antibiotic within 5 day first dose chemotherapy . Patients treatment lithium . Chronic use oral corticosteroid . Splenomegaly unknown origin physical examination and/or computerized tomography scan ultrasound condition cause splenomegaly , e.g. , thalassemia , glandular fever , hemolytic anemia , malaria . Myeloproliferative myelodysplastic disorder , sickle cell disorder , illness condition opinion investigator may affect safety patient evaluation study endpoint . Increase potential risk Adult Respiratory Distress Syndrome . Pregnant nursing woman . Patients know seropositive human immunodeficiency virus ( HIV ) , acquire immunodeficiency syndrome ( AIDS ) define illness know immunodeficiency disorder . A known active abuse drug alcohol preclude patient participation evaluation study . Any known psychiatric condition . Any disease physical condition may allow adequate performance study assessment , lack access patient 's domiciliary , distance patient 's domiciliary clinic site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Granulocyte Colony Stimulating Factor ( G-CSF )</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Neutropenia</keyword>
</DOC>